Comparative Pharmacology
Head-to-head clinical analysis: CEQUA versus IMURAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEQUA versus IMURAN.
CEQUA vs IMURAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunosuppressant; binds to cyclophilin D in mitochondria, inhibiting opening of mitochondrial permeability transition pore (mPTP), which reduces T-lymphocyte activation and cytokine release. Also forms complex with cyclophilin A to inhibit calcineurin, suppressing IL-2 production and T-cell proliferation.
Imuran (azathioprine) is a purine antimetabolite that inhibits DNA synthesis by interfering with purine metabolism. It is converted in vivo to 6-mercaptopurine (6-MP), which is further metabolized to thioinosinic acid and thioguanine nucleotides. These metabolites inhibit de novo purine synthesis and incorporation of purines into nucleic acids, thereby suppressing T-cell proliferation and antibody production.
Instill one drop of 0.09% ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Initially 3-5 mg/kg/day orally once daily; maintenance dose 1-3 mg/kg/day orally once daily. IV dose equivalent to oral.
None Documented
None Documented
Terminal elimination half-life is approximately 8.4 hours (range 6-10 hours) in healthy adults; prolonged in hepatic impairment and pediatric patients.
Azathioprine: 0.16–0.75 h; 6-mercaptopurine: 1.5–4.7 h (terminal). Extended up to 5 h in renal impairment. Context: short half-life allows daily dosing; clinical effect persists due to active metabolites.
Primarily fecal (90%) with minor renal excretion (<1% unchanged drug). Biliary excretion is the major route for elimination of cyclosporine metabolites.
Primarily renal excretion of inactive metabolites; 50% as 6-thiouric acid and other metabolites; <2% unchanged. Minor biliary/fecal elimination (<10% total).
Category C
Category C
Immunosuppressant
Immunosuppressant